As over 20% of serum hemolytic activity in the cRBC lysis assay was reported to correlate with events such as dysphagia and dramatic increases in lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) levels in PNH patients27, this suggests that subcutaneous administration of SKY59 in humans may effectively suppress hemolytic activity in PNH patients. This evidence concerns the gene GPT and paroxysmal nocturnal hemoglobinuria.